These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 19227807

  • 1. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
    Cotter J, Oliveira P, Cunha P, Polónia J.
    Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
    [Abstract] [Full Text] [Related]

  • 2. Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study.
    Pascual JM, Rodilla E, Miralles A, Gonzalez C, Redon J.
    J Hypertens; 2006 Nov; 24(11):2277-84. PubMed ID: 17053551
    [Abstract] [Full Text] [Related]

  • 3. Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
    Inoue A, Babazono T, Iwamoto Y.
    Am J Hypertens; 2008 Mar; 21(3):317-22. PubMed ID: 18202667
    [Abstract] [Full Text] [Related]

  • 4. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW, Won YW, Yi JH, Kim HJ.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [Abstract] [Full Text] [Related]

  • 5. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers.
    Galceran J, Plana J, Felip A, Pou G, Vila J, Sobrino J.
    Expert Rev Cardiovasc Ther; 2010 Jun; 8(6):751-7. PubMed ID: 20528630
    [Abstract] [Full Text] [Related]

  • 6. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [Abstract] [Full Text] [Related]

  • 7. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S, Sar F, Bengi-Bozkurt O, Kazancioglu R.
    Kidney Blood Press Res; 2009 Jun; 32(4):268-75. PubMed ID: 19776644
    [Abstract] [Full Text] [Related]

  • 8. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
    Saito F, Fujita H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K, Takahashi N, Otsuka Y, Uchiyama T, Kanmatsuse K, Kushiro T.
    Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
    [Abstract] [Full Text] [Related]

  • 9. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
    Maione A, Nicolucci A, Craig JC, Tognoni G, Moschetta A, Palasciano G, Pugliese G, Procaccini DA, Gesualdo L, Pellegrini F, Strippoli GF, LIRICO study group.
    J Nephrol; 2007 Jan; 20(6):646-55. PubMed ID: 18046666
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J.
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [Abstract] [Full Text] [Related]

  • 12. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD.
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [Abstract] [Full Text] [Related]

  • 13. Renin-angiotensin system blockade and contrast-induced renal toxicity.
    Saudan P, Muller H, Feraille E, Martin PY, Mach F.
    J Nephrol; 2008 Feb; 21(5):681-5. PubMed ID: 18949722
    [Abstract] [Full Text] [Related]

  • 14. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

  • 15. Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study.
    Marin P, Julve R, Chaves FJ, Giner V, Pascual JM, Armengod ME, Redon J.
    J Hum Hypertens; 2004 Jan; 18(1):25-31. PubMed ID: 14688807
    [Abstract] [Full Text] [Related]

  • 16. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA, Reboldi G.
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [Abstract] [Full Text] [Related]

  • 17. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Mar; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

  • 18. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN.
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [Abstract] [Full Text] [Related]

  • 19. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease.
    Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS.
    J Hypertens Suppl; 2006 Mar; 24(1):S95-9. PubMed ID: 16601581
    [Abstract] [Full Text] [Related]

  • 20. Determinants and patterns of renin-angiotensin system inhibitors' prescription in the first year following kidney transplantation.
    Thilly N, Bayat S, Alla F, Kessler M, Briançon S, Frimat L.
    Clin Transplant; 2008 Mar; 22(4):439-46. PubMed ID: 18318741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.